Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 49-56

  Lustberg, Maryam B ^a   Pant, Shubham ^a   Ruppert, Amy S ^a   Shen, Tong ^b   Wei, Yong ^b   Chen, Ling ^b   Brenner, Lisa ^a   Shiels, Donna ^a   Jensen, Rhonda R ^a   Berger, Michael ^c   Mrozek, Ewa ^a   Ramaswamy, Bhuvaneswari ^a   Grever, Michael ^a   Au, Jessie L ^b   Wientjes, M Guillaume ^b   Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Metastatic breast cancer; Paclitaxel; Phase I; Phase II; Suramin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; DOCETAXEL; PACLITAXEL; SURAMIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; METASTASIS; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LEUKOPENIA; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; PACLITAXEL; SURAMIN; TAXOIDS; TREATMENT OUTCOME;

EID: 84863461112     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1887-x     Document Type: Article

References (38)

1. Song S, Wientjes MG, Gan Y, Au JL (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97(15):8658-8663. doi:10.1073/pnas.140210697 (Pubitemid 30639729)
2. Gan Y, Wientjes MG, Au JL (2006) Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 23(6):1324-1331. doi:10.1007/s11095-006-0136-6 (Pubitemid 43946154)
3. Zhang Y, Song S, Yang F, Au JL, Wientjes MG (2001) Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299(2):426-433 (Pubitemid 32979652)
4. Song S, Yu B, Wei Y, Wientjes MG, Au JL (2004) Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 10(18 Pt 1):6058-6065. doi:10.1158/1078-0432. CCR-04-0595 (Pubitemid 39287510)
5. Song S, Wientjes MG, Walsh C, Au JL (2001) Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 61(16):6145-6150 (Pubitemid 32762551)
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205-216
7. Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Au JL (2006) Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res 23(6):1265-1274. doi:10.1007/s11095-006-0165-1 (Pubitemid 43946148)
8. Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK (2001) A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 12(5):605-614 (Pubitemid 32519911)
9. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL (2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol 19(11):1903-1909. doi:10.1093/annonc/mdn412
10. George S, Dreicer R, Au JJ, Shen T, Rini BI, Roman S, Cooney MM, Mekhail T, Elson P, Wientjes GM, Ganapathi R, Bukowski RM (2008) Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 6(2):79-85. doi:10.3816/CGC.2008.n.012
11. Eisenberger MA, Reyno LM (1994) Suramin. Cancer Treat Rev 20(3):259-273 (Pubitemid 24213089)
12. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53(10 Suppl):2239-2248
13. Waltenberger J, Mayr U, Frank H, Hombach V (1996) Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28(7):1523-1529. doi:10.1006/jmcc.1996.0142 (Pubitemid 26340906)
14. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR (1996) A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 39(1-2):1-8 (Pubitemid 26400654)
15. Dreicer R, Smith DC, Williams RD, See WA (1999) Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 17(2):183-186
16. Falcone A, Pfanner E, Cianci C, Danesi R, Brunetti I, Del Tacca M, Conte PF (1995) Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. Cancer 75(2):440-443
17. Falcone A, Pfanner E, Brunetti I, Allegrini G, Lencioni M, Galli C, Masi G, Danesi R, Antonuzzo A, Del Tacca M, Conte PF (1998) Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU?LV-based chemotherapy. Tumori 84(6):666-668 (Pubitemid 29086523)
18. Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, Masi G, Ricci S, Del Tacca M, Conte P (1999) Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 86(3):470-476. doi:10.1002/(SICI)1097-0142(19990801)86:3\470:AID- CNCR15[3.0.CO;2-7 (Pubitemid 29347409)
19. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C (1997) Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol 36(2):171-174 (Pubitemid 27168755)
20. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24(27):4384-4390. doi:10.1200/JCO.2005.05.1383 (Pubitemid 46630975)
21. Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL (2005) Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol 174(1):322-327. doi:10.1097/01.ju.0000161594.86931.ea (Pubitemid 40825750)
22. Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgo AJ, Fischer B, DeHoff C, Chen D, Yeh TK, Song S, Grever M, Au JL (2003) Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 9(9):3303-3311 (Pubitemid 37082724)
23. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsehe HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V (2007) Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 7(6):471-479. doi:10.3816/CBC.2007.n.004 (Pubitemid 46424284)
24. www.clinicaltrial.gov
25. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676. doi:10.1056/NEJMoa072113
26. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27(30):4966-4972. doi:10.1200/JCO.2008.21.6630
27. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA (2007) Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 7(6):465-470 (Pubitemid 46424283)
28. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25(23):3399-3406. doi:10.1200/JCO.2006. 08.9102 (Pubitemid 47310875)
29. Walsh CT, Wei Y, Wientjes MG, Au JL (2008) Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance. J Transl Med 6:4. doi:10.1186/1479-5876-6-4
30. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-5685. doi:10.1158/1078-0432.CCR-04-2421 (Pubitemid 41170290)
31. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L (2007) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13(7):2061-2067. doi:10.1158/1078-0432.CCR-06-2078 (Pubitemid 46649873)
32. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A (2010) Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102(2):316-324. doi:10.1038/sj.bjc.6605489
33. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20(2):272-277. doi:10.1093/annonc/mdn624
34. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW (2007) Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7(5):362-365. doi:10.1038/sj.tpj.6500434 (Pubitemid 47484774)
35. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16(10):3353-3361 (Pubitemid 28481632)
36. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19(22):4216-4223 (Pubitemid 33081639)
37. Lombardi D, Crivellari D, Scuderi C, Magri MD, Spazzapan S, Sorio R, Di Lauro V, Scalone S, Veronesi A (2004) Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 90(3):285-288 (Pubitemid 38981273)
38. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and Leukemia group B protocol 9840. J Clin Oncol 26(10):1642-1649. doi:10.1200/JCO.2007.11.6699